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a b s t r a c t
This study aimed to determine the excess length of stay, extra expenditures, and attributable
mortality to healthcare-associated S. aureus bloodstream infection (BSI) at a teaching hospi-
tal in central Brazil. The study design was a matched (1:1) case-control. Cases were deﬁned
as patients > 13 years old, with a healthcare-associated S. aureus BSI. Controls included
patients without an S. aureus BSI, who were matched to cases by gender, age (± 7 years),
morbidity, and underlying disease. Data were collected from medical records and from the
Brazilian National Hospital Information System (Sistema de Informac¸ões Hospitalares do
Sistema Único de Saúde – SIH/SUS). A Wilcoxon rank sum test was performed to compare
length of stay and costs between cases and controls. Differences in mortality between cases
and controls were compared using McNemar’s tests. The Mantel-Haenzel stratiﬁed analy-
sis was performed to compare invasive device utilization. Data analyses were conducted
using Epi Info 6.0 and Statistical Package for Social Sciences (SPSS 13.0). 84 case-control
pairs matched by gender, age, admission period, morbidity, and underlying disease were
analyzed. The mean lengths of hospital stay were 48.3 and 16.2 days for cases and controls,
respectively (p<0.01), yielding an excess hospital stay among cases of 32.1 days. The excess
mortality among cases compared to controls that was attributable to S. aureus bloodstream
infection was 45.2%. Cases had a higher risk of dying compared to controls (OR 7.3, 95% CI
3.1-21.1). Overall costs of hospitalization (SIH/SUS) reached US$ 123,065 for cases versus US$
40,247 for controls (p < 0.01). The cost of antimicrobial therapy was 6.7 fold higher for cases
compared to controls. Healthcare-associated S. aureus BSI was associated with statisticallysigniﬁcant increases in length of hospitalization, attributable mortality, and economic bur-
den. Implementation of measures to minimize the risk of healthcare-associated bacterial
infections is essential.
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Introduction
Bloodstream infections (BSIs) are serious and potentially fatal
events associated with high morbidity and mortality rates.
Mortality rates among patients with BSIs vary across stud-
ies, most likely due to patient co-morbidities and etiological
agents.1–4 AlthoughBSIs arenot themost frequent healthcare-
associated infection,5 they have been associated with heavy
clinical and economic burdens in many settings.6–19 In gen-
eral, mortality rates associated with BSIs are high worldwide,
in spite of technological advances and availability of effec-
tive antimicrobial drugs.1,3,16,19–21 Although a consensus on
the topic has not been reached, several studies have shown a
signiﬁcantly higher attributable mortality due to healthcare-
associatedBSIs.3,6,8,9,13,16 In contrast, other studies didnot ﬁnd
differences in mortality rates between patients with and with-
out BSIs, after controlling for somepotential confounders such
as age and comorbidities.12,22 Discrepant results across stud-
ies may reﬂect differences in study methodology, severity of
infection, hospital conditions, or bacteriological proﬁles.
Although the bacteriological proﬁle of healthcare-
associated BSIs varies with time period, country, and
hospital, S. aureus is one of the most frequently isolated
BSI pathogens worldwide.4,21,23,24 S. aureus BSIs have been
associated with unfavorable clinical outcomes in many
studies.3,25 Some studies showed higher impact on costs and
mortality rates due to methicillin-resistant S. aureus (MRSA),
compared to methicillin-susceptible strains (MSSA).10,26–29
Few studies have investigated the impact of S. aureus on
costs and attributable mortality rates in Latin America.9,26
The objective of the current study was to estimate increased
hospital stay, increased direct costs, and mortality attributed
to healthcare-associated BSI caused by S. aureus, in patients
admitted to a teaching hospital in Brazil.
Methods
Population and setting
This study was conducted in a public, tertiary-care teaching
hospital in the city of Goiânia, the capital of the Brazilian state
of Goiás, which has a population of approximately 1.2 million.
During the study period (2000-2001), approximately 12,000
patients per year had been admitted to that hospital; 118
patients had amicrobiologically conﬁrmedBSI due to S. aureus.
Blood cultures were taken on a routine basis when infection
was suspected. A total of 34 cases were excluded from the
analysis: seven had incomplete clinical data to rule out con-
tamination, 24 cases had community acquired BSI, and three
caseswere younger than 13 years old. The remaining 84 adults
had at least one episode of clinically signiﬁcant healthcare-
associated BSI. All clinical and laboratory data were reviewed
by an infectious diseases specialist physician. More detailed
information has been published previously.25Study design
This was a 1:1 matched case-control study, conducted from
2000 to 2001. Patients older than 13 years of age, with12;16(6):503–509
an episode of clinically signiﬁcant healthcare-associated BSI
caused by S. aureus were classiﬁed as cases. Controls were
selected from patients without a positive blood culture hos-
pitalized during the same period as the cases. Controls were
matched by gender, age (±7 years), morbidity, and underlying
disease according to the 10th edition of the International Clas-
siﬁcation of Diseases and Related Health Problems (ICD-10). In
addition, the length of hospital stay of the controls had to be
as close as possible to the length of stay of the cases, from
admission until the onset of BSI.
Data collection and deﬁnitions
Clinical and microbiological data were abstracted from med-
ical records and hospital laboratory reports. Financial data
were extracted from the Brazilian National Hospital Infor-
mation System (Sistema de Informac¸ões Hospitalares do
Sistema Único de Saúde – SIH/SUS). Infections were clas-
siﬁed as healthcare-associated when they occurred at least
48hours after hospital admission and were not complica-
tions of infectionspresent uponadmission, orwhen infections
were detected following hospital discharge but were related
to the previous admission.30 Healthcare-associated BSIs were
conﬁrmed by a S. aureus positive blood culture (BACTEC
9120-Becton Dickinson) in the presence of at least one of
the following clinical manifestations: fever or hypothermia
deﬁned by an axillary temperature >38 ◦C or<36 ◦C, respec-
tively; cardiac rate higher than 90 bpm; respiratory rate higher
than 20 ipm or PaCO2<32mmHg; leukocyte count > 12,000
leucocytes/mm3 or<4,000 leucocytes/mm3, or > 10% of imma-
ture forms; organ disorder, hypoperfusion, or hypotension; or
persistent sepsis-induced hypotension in spite of adequate
ﬂuid replacement.30,31
The severity of the underlying disease at admission was
evaluated according to the criteria proposed by McCabe and
Jackson, with modiﬁcations, and was classiﬁed into three
groups: rapidly fatal disease, potentially fatal disease, and
non-fatal disease or absence of underlying disease.32
Attributable mortality was deﬁned as the excess mortality
caused by BSI and was calculated by subtracting the mortality
rate of the control patients from the mortality rate of the case
patients with BSI. The excess length of hospital stay and the
excess duration of use of invasive devices were each deﬁned
as the difference between the values obtained for cases and
controls. The excess cost attributed to healthcare-associated
BSIs was deﬁned as the difference in overall costs between
cases and controls. Cost data were obtained from the Brazilian
National Public Health Reimbursement System for Hospital
Admission (Sistema de Informac¸ão Hospitalar Data – SUS).33
Reimbursements are made using predeﬁned values for each
particular disease or health state. This compensation system
does not account for costs due to antimicrobials, parenteral
nutrition, nor blood products used during the hospitaliza-
tion. The medical records of each patient were reviewed to
check for antimicrobials, blood products, and parenteral nutri-
tion required for cases and controls. Estimates of costs for
antimicrobial agents were based on the reference table used
by private health insurance plans. Costs were calculated in
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Sulfamethoxazole / trimethoprim
Ampicillin / sulbactam
Clindamycin
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Fig. 1 – Distribution of antimicrobials prescribed for casesbraz j infect d i s .
razilian reais (R$) and then converted to United States dollars
US$) using the exchange rate of 2001.
tatistical analysis
omparisons between cases and controls were conducted
sing Student’s t-test for continuous variables and the Fisher’s
xact test or chi-squared tests for categorical variables. The
ilcoxon rank-sum test was used to compare length of hos-
ital stay anddirect hospital costs between cases and controls.
cNemar’s test was used to compare mortality rates between
ases and controls. A Mantel-Haenszel stratiﬁed analysis,
ccording to ICU admission, was performed to evaluate inva-
ive device utilization, of both cases and controls. Odds ratios
ORMH) and95%conﬁdence intervals (95%CIs)were calculated.
p-values of less than 0.05were considered to be statistically
igniﬁcant.
Data analyses were conducted using Epi Info 6.0 and Sta-
istical Package for Social Sciences version 13.0 (SPSS). The
tudy was approved by the Ethics Committee for Research on
umans and Animals of the Universidade Federal de Goiás.
esults
ighty four cases of healthcare-associated S. aureus BSI in
atients older than 13 years of age were identiﬁed. These
ases were successfully mached, resulting in 84 case-control
airs matched by gender, age, admission period, morbidity,
nd underlying disease. Male patients represented 57.0% of
ases. Participants’ ages ranged from 14 to 91 years; no dif-
erence between the mean ages of cases and controls was
etected (p= 0.73). Cases and controls did not differ with
espect to the severity of the underlying disease at admission
p= 0.44), the presence of co-morbidities (p = 0.31), or the use
f immunosuppressant therapies (p= 0.10). Diagnoses of dia-
etes mellitus and chronic renal failure were more frequent
mong cases, compared to controls, and the risk of presenting
t least one episode of healthcare-associated infection was
.7 times higher among cases, compared to controls (Table 1).
mong the 84 cases, 49 (58.3%) had a BSI due to MRSA. The
edian length of hospital stay prior to hospital-associated BSI
as 18.5 days, ranging from two to 154 days. Cases were more
requently admitted to the intensive care unit (ICU) compared
o controls (p < 0.01). A stratiﬁed analysis for invasive device
tilization, adjusted for ICU admission, disclosed that cases
equired central venous catheters (ORMH 73.8, 95% CI 20.4-
09.3) and mechanical ventilation (ORMH 6.3, 95% CI 1.8-22.9)
ore frequently than controls. No statistically signiﬁcant dif-
erence was found between cases and controls regarding the
se of either urinary catheters (ORMH 2.2, 95% CI 0.9-5.1), or
urgical procedures (ORMH 1.2, 95% CI 0.6-2.6). Cases received
ore parenteral nutrition (ORMH 6.6, 95%CI 2.1-74.5) than con-
rols.
The raw mortality rates for cases and controls were 57.1%48/84) and 11.9% (10/84), respectively (p<0.01). Attributable
ortality to S. aureus BSI was 45.2%. Mortality associated with
SI was higher in cases compared to controls (OR 7.33, 95% CI
.11-21.1).and controls during hospitalization.
The median length of hospital stay among cases was 37
days, ranging from two to 390 days. The median length of hos-
pital stay among controls was 12 days, ranging from two to 57
days. An excess of 2,700 hospitalization days was attributed
to BSI among cases, compared to controls. A statistically sig-
niﬁcant difference was observed between cases and controls
regarding the mean duration of use of invasive devices, such
as urinary catheter and mechanical ventilation. Compared to
controls, cases had 763 excess ICU days, in addition to a longer
duration of use of invasive devices, including parenteral nutri-
tion, mechanical ventilation, and urinary catheter (Table 2).
The average number of episodes of healthcare-associated
BSI per case was 3.4; the average number of episodes of
healthcare-associated BSI per control was 0.3. Among cases,
71 pathogens, in addition to S. aureus, were isolated from var-
ious body sites during hospitalization. Gram-negative bacilli
represented the majority of isolates. Fig. 1 presents antimi-
crobial agents prescribed for cases and controls. Cases were
prescribed more antimicrobials than controls. Fifty-two out
of 84 cases received vancomycin, while only three controls
required this drug.
The total hospitalization direct costs (SIH-SUS) were US$
123,065 (US$ 1,465/patient) for cases, and US$ 40,247 (US$
479/patient) for controls. The hospitalization cost for the cases
was 3.1 times higher compared to controls. The excess hospi-
talization cost attributable to healthcare-associated S. aureus
BSI of cases compared to controls was US$ 82,818. Costs due
to use of antimicrobial agents were US$ 119,210 among cases,
and US$ 17,650 among controls. The total cost attributable
to BSI was US$ 101,559. The mean costs due to antimicro-
bial agents were US$ 1,419 per case and US$ 210 per control.
Antimicrobials expenditure for cases was 6.7 times higher
than for controls (Table 3).
An analysis of direct costs among the subset of patients
who survived BSI, including 36 cases and 74 controls, showed
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Table 1 – Baseline characteristics of 84 cases with healthcare-associated S. aureus bloodstream infections (BSIs) and 84
matched controls.
Characteristics Cases Controls p-value
n=84 (%) n=84 (%)
Gender
Male 47 (57.0) 47 (57.0) -
Age (years)
Mean (SD) 47.7 (19.1) 48.7 (18.1) 0.73
IQR (25% - 75%) 33.0 – 62.5 35.5-63.0
Severity of underlying disease
Rapidly fatal 6 (7.1) 4 (4.8) 0.44
Fatal 28 (33.4) 26 (31.0)
Nonfatal disease or absence of underlying disease 50 (59.5) 54 (64.2)
Presence of co-morbidities
None 22 (26.2) 28 (33.3) 0.31
At least one 62 (73.8) 56 (66.6)
Type of co-morbidities
Immunosuppressive therapy 25 (29.8) 16 (19.0) 0.11
Diabetes mellitus 21 (25.0) 12 (14.3) 0.03
Chronic renal failure 21 (25.0) 7 (8.3) < 0.01
Cancer 5 (5.9) 5 (5.9) 1.00
Episodes of infections other than BSI
Healthcare-associated 282 (335.7) 29 (34.5) < 0.01
Community-acquired 18 (21.4) 13 (15.5) 0.32SD, standard deviation; IQR, interquartile range.
that costs were US$ 38,647 (US$ 1,073/patient) among cases
and US$ 34,230 (US$ 462/patient) among controls. Considering
expenses among survivors, the reimbursement cost for cases
was 1.1 times higher than for controls. The ICU cost among
cases was 20.4 times higher than among controls.
Table 2 – Length of stay and exposure to invasive procedures o
bloodstream infections (BSIs) and 84 matched controls.
Cases Controls
Length of stay
Total days 4061 1361
Mean (SD) 48.3 (52.8) 16.2 (12.1)
Median (range) 37.0 (2–390) 12.0 (2–57)
Intensive care unit
Total days 784 24
Mean (SD) 9.4 (14.8) 0.3 (0.9)
Median (interval) 3.0 (0–66) 0.0 (0–7)
Standard parenteral nutrition
Total days 946 26
Mean (SD) 11.3 (44.7) 0.3 (2.0)
Median (interval) 0.0 (0–390) 0.0 (0–14)
Urinary catheter
Total days 893 79
Mean (SD) 10.6 (15.6) 0.9 (2.2)
Median (interval) 4.0 (0–95) 0.0 (0–15)
Mechanical ventilation
Total days 596 16
Mean (SD) 7.1 (11.9) 0.2 (0.9)
Median (interval) 0.0 (0–47) 0.0 (0–7)
SD, standard deviation.DiscussionThis study identiﬁed an increased length of hospital stay, a
higher mortality rate, and an excess of direct costs related to
f 84 cases with healthcare-associated S. aureus
Attributable difference p-value
2700
32.1 < 0.01
763
9.1 < 0.01
920
11.0 < 0.01
814
1.6 < 0.01
580
6.9 < 0.01
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Table 3 – Comparison of direct costs (US$) for 84 patients with S. aureus hospital acquired bacteraemia and their matched
controls.
Costs (US$) All patients
Cases (n=84) Controls (n=84) Difference attributed
to infection
Reason
(Cases/controls)
Total For individual Total For individual
Total cost AH 123065 1 465 40 247 479 82 818 3.1
Antimicrobials 119 210 1 419 17 651 210 101 559 6.7
Daily ICU 21580 257 1 058 13 20 522 20.4
Standard parenteral nutrition 10655 127 293 3 10 362 36.4
135
unit.
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US$, dolar; AH, authorization for hospitalization; ICU, intensive care
ealthcare-associated S. aureus BSI in a teaching hospital in
entral Brazil. The difference in mortality rates between cases
nd controls was 45.2%, suggesting that approximately half
f the deaths could be attributed to BSI. Therefore, mortal-
ty could be reduced, at least in part, by adopting effective
easures to control hospital infections. The cases enrolled
n the study were more frequently admitted to the ICU, and
xperienced a longer duration of use of invasive procedures,
ompared to controls which could have been due to cases
eing generally more ill. However, cases and controls were
ot different at admission regarding reasons for hospitaliza-
ion or severity of underlying disease. Cases and controls were
lso similar with respect to the presence of co-morbidities,
einforcing the hypothesis that differences in morbidity and
ortality rates could be attributed to healthcare-associated
SIs.
The attributable mortality to healthcare-associated BSI
eported herein has been described in a few previously
ublished studies conducted in Latin America.9,26 Studies
onducted around the world, mainly in the United States
nd Europe, have shown that hospital-acquired BSIs were
ssociated with signiﬁcant attributable mortality.3,7,11,15,17 In
ontrast, other studies have not demonstrated differences in
ttributable mortality due to hospital-acquired BSIs in ICU
atients, although increased hospital costs were evident.12,18
Methodological issues, such as the selection of matching
ariables, heterogeneous patient populations, and miscel-
aneous microbiological agents causing BSIs could partially
xplain these divergent results. Another factor that might
ave inﬂuenced results, speciﬁcally with respect to total costs
f treating BSIs, was susceptibility to antimicrobial agents.
ther investigators demonstrated higher costs when treating
RSA BSIs vs. MSSA BSIs.27
Discussions of methodological issues in epidemiologic
tudies of outcomes related to healthcare-associated BSIs
nclude the best strategies to evaluate attributable mortality,
xcess costs, and increased duration of hospital stays.3,8,34
omparison of infected patients (cases) and non-infected
atients (controls) matched by a given parameter would par-
ially reduce the bias created by the severity of the underlying
isease. Another approach aimed at increasing the homo-
eneity of the study population is to deﬁne one etiological
gent (S. aureus) and one infection site.6,12 Yet another strategy
ould be the use of severity scores that would serve to com-
are cases and controls. However, severity scores or scales,13 8 815 8.8
such as the McCabe and Jackson score, Acute Physiology
and Chronic Health Evaluations (APACHE), and the Simpliﬁed
Acute Physiology Score (SAP) were developed to evaluate the
risk of death during hospitalization, and they have not been
validated for other purposes.
In this study, cases remained in the hospital an average of
32.1 days longer than controls. The cases also stayed longer
in the ICU than controls and also required a larger num-
ber of invasive procedures, possibly attributable to the BSI.
An association between BSI and increased length of hospi-
tal stay has been described previously; estimates of excess
length of hospital stay have ranged widely from 1.2 to 32
days.6–9,17,19,35,36 Differences across studies may be partially
explained by limiting the study samples to survivors or by
choices of matching variables.
Patients hospitalized longer are at greater risk of con-
tracting a healthcare-associated infection; however, length of
hospital stay is also a marker for the severity of the underly-
ing disease. Therefore, an important matching variable would
be the length of hospital stay previous to BSI. The length of
hospital stay among controls should be greater than or equal
to the length of hospital stay prior to BSI for cases. Approxi-
mately 40% of cases in the present study had a hospitalization
length prior to bacteremia that were longer than that of the
matched control. This may suggest that cases could had more
severe diseases, and points to a possible overestimation of
both length of hospital stay and costs among cases, compared
to controls.
It should also be noted that the sum of the direct costs for
antimicrobial agents among cases represented 96.9% of the
total amount paid to the hospital as reimbursement accord-
ing to SIH-SUS. For the controls, direct costs for antimicrobial
agents represented 45.7% of the total amount paid to the hos-
pital as reimbursement.
In the present study, the percentage of MRSA among cases
with healthcare-associated BSI was high, similar to compa-
rable data from studies conducted in several centers in the
Americas and Europe.13,23,25,26 In addition to economic impli-
cations, the large-scale use of vancomycin may contribute to
an increased prevalence of resistant microorganisms.37
This study showed that healthcare-associated S. aureus
BSIs are associated with higher mortality, longer hospital
stays, and increased costs. This knowledge reinforces the
institutional responsibility to develop strategies for effective
infection prevention.
i s . 20
r
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3508 braz j infect d
Conﬂict of interest
All authors declare to have no conﬂict of interest.
Acknowledgements
The authorswould like to thankNational Council for Scientiﬁc
andTechnological Development (CNPq) for the research schol-
arships granted to Marília D. Turchi (Proc. no. 306928/2010-8)
and Celina M.T. Martelli.
e f e r e n c e s
1. Pittet D, Wenzel RP. Nosocomial bloodstream infections.
Secular trends in rates, mortality, and contribution to total
hospital deaths. Arch Intern Med. 1995;155:1177–84.
2. Correa L, Pittet D. Problems and solutions in
hospital-acquired bacteraemia. J Hosp Infect. 2000;46:89–95.
3. Bearman GML, Wenzel RP. Bacteremias: a leading cause of
death. Arch Med Res. 2005;36:646–59.
4. Pien BC, Sundaram P, Raoof N, et al. The clinical and
prognostic importance of positive blood cultures in adults.
Am J Med. 2010;123:819–28.
5. Klevens RM, Edwards JR, Richards CL, et al. Estimating health
care-associated infections and deaths in US hospitals, 2002.
Public Health Rep. 2007;122:160–6.
6. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream
infection in critically ill patients: excess length of stay, extra
costs, and attributable mortality. JAMA. 1994;271:1598–601.
7. Jarvis WR. Selected aspects of the socioeconomic impact of
nosocomial infections: morbidity, mortality, cost, and
prevention. Infect Control Hosp Epidemiol. 1996;17:552–7.
8. Orsi GB, Di Stefano L, Noah N. Hospital-acquired,
laboratory-conﬁrmed bloodstream infection: increased
hospital stay and direct costs. Infect Control Hosp Epidemiol.
2002;23:190–7.
9. Rosenthal VD, Guzman S, Migone O, Crnich CJ. The
attributable cost, length of hospital stay, and mortality of
central line-associated bloodstream infection in intensive
care departments in Argentina: a prospective, matched
analysis. Am J Infect Control. 2003;31:475–80.
0. Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes
among hemodialysis-dependent patients with
methicillin-resistant or methicillin-susceptible Staphylococcus
aureus bacteremia. Infect Control Hosp Epidemiol.
2005;26:175–83.
1. Pirson M, Dramaix M, Struelens M, Riley TV, Leclercq P. Costs
associated with hospital-acquired bacteraemia in a Belgian
hospital. J Hosp Infect. 2005;59:33–40.
2. Blot SI, Depuydt P, Annemans L, et al. Clinical and economic
outcomes in critically ill patients with nosocomial
catheter-related bloodstream infections. Clin Infect Dis.
2005;41:1591–8.
3. Thompson DS. Estimates of the rate of acquisition of
bacteraemia and associated excess mortality in a general
intensive care unit: a 10 year study. J Hosp Infect.
2008;69:56–61.
4. Kilgore M, Brossette S. Cost of bloodstream infections. Am J
Inf Control. 2008;36. S172.e1-S172.e3.
5. Kothari A, Sagar V, Ahluwalia V, Pillai BS, Madan M. Costs
associated with hospital-acquired bacteraemia in an Indian
hospital: a case-control study. J Hosp Infect. 2009;71:143–8.
6. Tacconelli E, Smith G, Hieke K, Lafuma A, Bastide P.
Epidemiology, medical outcomes and costs of12;16(6):503–509
catheter-related boodstream infections in intensive care
units of four European countries: literature and
registry-based estimates. J Hosp Infect. 2009;72:97–103.
7. Vrijens F, Hulstaert F, Van de Sande S, Devriese S, Morales I,
Parmentier Y. Hospital-acquired, laboratory-conﬁrmed
bloodstream infections: linking national surveillance data to
clinical and ﬁnancial hospital data to estimate increasing
length to stay and healthcare costs. J Hosp Infect.
2010;75:158–62.
8. Niven DJ, Fick GH, Kirkpatrick AW, Grant V, Laupland KB. Cost
and outcomes of nosocomial bloodstream infections
complicating major traumatic injury. J Hosp Infect.
2010;76:296–9.
9. Burns A, Bowers L, Pak N, Wignall J, Roberts S. The excess cost
associated with healthcare-associated bloodstream infections
at Auckland City Hospital. N Z Med J. 2010;123:17–24.
0. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP,
Edmond MB. Nosocomial bloodstream infections in US
hospitals: analysis of 24,179 cases from a prospective
nationwide surveillance study. Clin Infect Dis. 2004;39:
309–17.
1. Guilarde AO, Turchi MD, Martelli CMT, Primo MGB, Batista LJA.
Bacteremias at a teaching hospital: etiology, antimicrobial
susceptibility pattern and risk factors for mortality. Rev Assoc
Med Bras. 2007;53:34–8.
2. Laupland KB, Zigun DA, Davies HD, Church DL, Louie TJ,
Doing CJ. Population-based assessment of intensive care
unit-acquired bloodstream infections in adults: incidence,
risk factors, and associated mortality rate. Crit Care Med.
2002;30:2462–7.
3. Sader HS, Jones RN, Andrade-Baiocchi S, Biedenbach DJ.
Four-year evaluation of frequency of occurrence and
antimicrobial susceptibility patterns of bacteria from
bloodstream infections in Latin American medical centers.
Diagn Microbiol Infect Dis. 2003;44:273–80.
4. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of
health-care-associated infections and antimicrobial
resistance in patients admitted to European intensive-care
units: a cohort study. Lancet Infect Dis. 2011;11:30–8.
5. Guilarde AO, Turchi MD, Martelli CMT, Primo MGB.
Staphylococcus aureus bacteraemia: incidence, risk factors and
predictors for death in a Brazilian teaching hospital. J Hosp
Infect. 2006;63:330–6.
6. Conterno LO, Wey SB, Castelo A. Risk factors for mortality in
Staphylococcus aureus bacteremia. Infect Control Hosp
Epidemiol. 1998;19:32–7.
7. Rubio-Terrés C, Garau J, Grau S, Martinez-Martinez L. Cost of
bacteraemia caused by methicillin-resistant vs.
methicillin-susceptible Staphylococcus aureus in Spain: a
retrospective cohort study. Clin Microbiol Infect.
2010;16:722–8.
8. Harbarth S, Rustchmam O, Sudre P, Pittet D. Impact of
methicillin resistance on the outcome of patients witch
bacteremia caused by Staphylococcus aureus. Arch Intern Med.
1998;158:182–9.
9. Crosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW,
Carmeli Y. The impact of methicillin resistance in
Staphylococcus aureus bacteremia on patient outcomes:
mortality, length of stay, and hospital charges. Infect Control
Hosp Epidemiol. 2005;26:166–74.
0. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC
deﬁnitions for nosocomial infections, 1988. Am J Infect
Control. 1988;16:128–40.
1. Bone RC, Balk RA, Cerra FB, et al. Deﬁnitions for sepsis and
organ failure and guidelines for the use of innovative
therapies in sepsis. The ACCP/SCCM Consensus Conference
Committee. American College of Chest Physicians/Society of
Critical Care Medicine. Chest. 1992;101:1644–55.
201
3
3
3
3
3braz j infect d i s .
2. McCabe WR, Jackson GG. Gram-negative bacteremia. I.
Etiology and ecology. Arch Intern Med. 1962;110:
847–55.
3. Paim J, Travassos C, Almeida C, Bahia L, Macinko J. The
Brazilian health system: history, advances, and challenges.
Lancet. 2011;377:1778–97.4. Verbrugh HA. Impact of methicillin-resistant Staphylococcus
aureus infection on morbidity and costs in healthcare
facilities. Infection Control Hosp Epidemiol. 2006;27:
994–5.
32;16(6):503–509 509
5. Barnett AG, Graves N, Rosenthal VD, Salomão R,
Rangel-Frausto MS. Excess length of stay due to a central line
associated blood stream infections in intensive care units in
Argentina, Brazil and Mexico. Infect control Hosp
Epidemiolol. 2010;31:1106–14.
6. Köck R, Becker K, Cookson B, et al. Methicilin-resistant
Staphylococcus aureus (MRSA): burden of disease and control
challenges in Europe. Euro Surveill. 2010;15:1–9.
7. Hawkey PM. The growing burden of antimicrobial resistance. J
Antimicrob Chemother. 2008;62:i1–9.
